Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Blood Plasma Partitioning

Certain drugs are highly bound to red blood cells (RBC) whilst others are highly bound to plasma proteins. As pharmacokinetics are mostly measured from plasma samples, binding to RBC can lead to dramatically miscalculated blood-derived pharmacokinetic parameters, e.g. clearance, AUC, Cmax and Vss.

Like plasma protein binding, binding to red blood cells (RBC) can significantly reduce a drug’s free plasma concentration, i.e. the fraction of drug that is available for its pharmacological action and its elimination. A compound’s pharmacodynamic and pharmacokinetic profile can hence be severely affected by its blood partitioning. Likewise, accumulation in RBC can lead to toxicity in these cells. It is, therefore, important to determine blood partitioning early during the drug discovery process.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.